87-89 have categorically remarked absence of suicidal ideation in both the cases who had developed pseudoparkinsonism and akathisia while being treated with fluoxetine alone and in combination with heloperidol & lithium. Akathisia had appeared in these cases on 5th day in easel and 6th & 14th day in case 2 respectively. The absence of suicidal ideation has been attributed to early detection and treatment of akathisia. The development of akathisia and emergence/ aggravation of suicidality is a complex issue. Suicidal ideation has been observed with anti depressant pharmacotherapy and has not been proved to be associated with any specific type of antidepressant. Whether certain anti depressants precipitate and or aggravate suicidal ideation in a subgroup of patients, responder as well as non responder to therapy is uncertain. It is unrelated to the dosage of fluoxetine (Mann & Kapur,1991) . Suicidal ideation has been observed appearing suddenly, concurrent with neuroleptic induced akathisia and disappeared when akathisia was treated (Drake & Ehrlich, 1985) . Fluoxetine induced akathisia is indistinguishable from that of neuroleptic induced akathisia (Lipinski et al., 1989) . The proposed link between f'uoxetine induced akathisia and suicidality is explained on the basis of four neuron model of extrapyramidal motor system, in which increased serotonin activity by inhibiting the nigrostriatal dopamine tract, is capable of inducing a syndrome named Extra Pyramidal Dysphoric Reactions, one extreme form of manifestation of which is suicidal ideation (Hamilton & Opler,1992) . I would like to raise a question and request for comments from the author on severity of akathisia and its relation to suicidality, which is lacking in the present case reports. Suicidality may be related to severity of THE EDITOR akathisia rather than its duration.
RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
Sir, We read with intrest the study by Agarwal etal.(1998) titled 'Risperidone in Indian patients with Schizophrenia'. Limitations of an open-label study not withstanding, this study has a few shortcomings which we would like to mention.
First, the patients entering the study were rated on Positive and Negative Symptom Scale (PANSS) after a week's wash-out period. A more meaningful approach would have been to rate the patients at first contact while they were still on medication and then a week after wash-out. This enables an investigator to know whether withdrawal from neuroleptics contributed to any improvement in symptomatology. It is known that many patients under routine clinical treatment actually benefit from a reduction in their medication dose rather than an increase (Johnson & Johnson,1995) . This may be particularly true in patients with extrapyramidal
